Medical Device Registration in APAC: The Complete Reference Guide

Medical device registration in Asia Pacific is not a single process. It is a collection of country-specific pathways, each with its own regulatory authority, classification logic, documentation expectations, and review culture that must be understood and planned for individually before any submission begins.

This guide is designed as a reference you can return to throughout your APAC market entry planning. It covers what registration actually means in each major market, what the regulatory authorities prioritize, where requirements diverge most, how the registration process unfolds in practice, and what the most current 2026 developments mean for your submission strategy.

For strategic and operational insights on navigating APAC, including how to avoid the most costly submission pitfalls and how to use reliance pathways effectively, see our companion post and webinar replay here- Inside Asia Pacific: How to Navigate the APAC Regulatory Region. 

What “Medical Device Registration in APAC” Actually Means

At a high level, medical device registration in APAC refers to obtaining authorization from a country-specific regulatory authority to market a device. In practice, registration can mean very different things depending on the market:

In some countries it resembles a structured approval process with extensive technical review. In others it functions more like a listing supported by conformity evidence. In still others, local testing or clinical data generation is a prerequisite before submission even begins.

This is where global teams consistently lose time, treating registration, approval, and listing as interchangeable concepts when regulators do not. Understanding the distinction for each target market before building your documentation strategy is not optional. It is foundational.

Key Regulatory Authorities: Who They Are and What They Prioritize

The APAC regulatory landscape is defined by its major national authorities. What matters for planning purposes is not just who they are, but what each one prioritizes during review.

 

What stands out across this table is not just timeline variation, it is variation in what each regulator fundamentally cares about. China scrutinizes local clinical evidence and testing. Japan scrutinizes QMS and clinical data in parallel. South Korea has built the most advanced framework for AI devices. Australia and Singapore offer the fastest pathways for well-documented devices from recognized markets.

Reliance Pathways: What Is Available in 2026

Reliance pathways, where one regulator accepts or uses the assessment of a trusted reference authority to shorten its own review, have expanded significantly across APAC in 2025 and 2026. This is one of the most practically important developments for manufacturers with existing FDA clearance or EU CE marking.

Reference authorities whose approvals unlock reliance across APAC:

According to the APACMed Regulatory Reliance Pathways Tracker, approvals from the following reference authorities are accepted in multiple APAC markets:

• US FDA: Accepted in Australia, Bangladesh, Hong Kong, India, Malaysia, Pakistan, Singapore, Sri Lanka, Taiwan, Thailand, and Vietnam
• EU (Notified Bodies): Accepted in Australia, Bangladesh, Hong Kong, India, Malaysia, Pakistan, Singapore, Sri Lanka, Taiwan, Thailand, and Vietnam
• Japan PMDA/MHLW: Accepted in Australia, Bangladesh, Hong Kong, India, Malaysia, Pakistan, Singapore, Sri Lanka, Taiwan, Thailand, and Vietnam
• Singapore HSA: Accepted in Australia, Hong Kong, Sri Lanka, Thailand, and the Philippines
• Australia TGA: Accepted in Bangladesh, Hong Kong, India, Malaysia, Pakistan, Singapore, Sri Lanka, Thailand, and Vietnam

Key 2025–2026 Bilateral Reliance Developments:

Singapore: Malaysia bilateral reliance program launched September 2025. The six-month pilot ran through February 2026 and has moved to ongoing implementation. Devices registered with Singapore HSA undergo a verification route through Malaysia’s MDA CAB, with a target review timeline of 30 working days, versus 60 working days under the standard conformity assessment route.

Malaysia: Thailand bilateral reliance pilot ran February to April 2026 for Class B, C, and D devices. Devices registered with the Thai FDA are eligible for the verification route through Malaysia MDA’s CAB. Devices registered with MDA undergo full submission in Thailand without external expert review.

Important Caveat:

Reliance does not eliminate your regulatory obligations. Documentation must be properly structured and aligned with the reliance market’s local requirements. A submission that works well for FDA will not automatically transfer without localization.

Where APAC Requirements Diverge Most

Even when APAC frameworks appear aligned with global standards from a distance, execution-level differences are significant enough to materially affect your strategy across five areas.

Classification. Even risk-based systems use different criteria. A device classified as Class II in one market may fall into a higher-risk category in another, this is especially common for software products, combination products, and borderline devices. Always conduct a country-specific classification assessment before finalizing documentation.

Clinical evidence. Some regulators accept foreign clinical data with minimal adaptation. Others require bridging studies or locally generated evidence. China, in particular, requires in-country clinical trials for many higher-risk device types. South Korea’s MFDS has detailed algorithm validation and performance monitoring requirements for AI-based devices.

Technical documentation. Most APAC markets reference formats similar to the STED (Summary Technical Documentation), but the required level of detail and how information must be structured varies. A dossier structured for EU MDR submission will typically need adaptation, sometimes substantial, before it meets local expectations.

Local representation. Most APAC countries require an in-country representative or license holder. This is not a formality. In many markets, the local representative legally owns the registration and is the primary party interacting with the regulator. The choice of representative can affect both your timeline and your long-term regulatory control.

Language and translation. In much of the world, English-language submissions with translated labeling are acceptable. Across much of Asia Pacific, full translation of all submission documents is required. This is a compliance requirement, not just a logistical one, poor translation creates misunderstandings with regulators that lead to deficiency questions and delays.

How APAC Registration Actually Unfolds: The Five-Step Process

Even though each country operates differently, most APAC registrations follow a similar sequence. The complexity lies in how each step is interpreted locally.

Step 1- Determine Device Classification. Classification is the first critical decision and the most common source of early delay. Misclassification leads to incorrect data requirements and forced resubmissions. Conduct this assessment country by country before any documentation work begins.

Step 2- Identify Market-Specific Requirements. This includes whether local testing is required, which standards apply, whether prior approvals can be leveraged via a reliance pathway, and what documentation format the authority expects.

Step 3- Prepare Technical Documentation. Core components typically include device description, risk management files, clinical evidence, and manufacturing information. The challenge is adapting each component to country-specific expectations rather than submitting a single global dossier.

Step 4-  Appoint Local Representatives. In many APAC markets, this step must be completed before submission. Do not treat this as an administrative afterthought. The representative you appoint has legal and operational implications that extend throughout the product’s lifecycle in that market.

Step 5- Submit and Respond to Deficiency Questions. Regulatory authorities across APAC regularly issue deficiency questions. In many markets, unlike the US and EU, there is no mandated manufacturer response timeframe, meaning the clock stops with each round of questions. Response quality and speed are within your control and directly determine your effective approval timeline.

Timelines: What the Published Numbers Don’t Tell You

Regulatory agencies publish review timelines and they are easy to find. What those numbers do not reflect is that the clock typically stops each time a regulator issues questions and in many APAC markets, there is no mandated timeframe for manufacturers to respond. A nominal 180-day review can quietly extend to two or three years if deficiency responses are not prioritized.

Additionally, country-specific testing requirements discovered late can add months to your timeline that have nothing to do with the regulatory review period itself. China’s local type testing requirements are the most common example, but they are not the only one.

The practical takeaway: the difference between your published timeline and your actual approval date is often within your control, but only if you plan for it from the start.

Post-Market Obligations: Approval Is Not the Finish Line

Post-market requirements across APAC are growing in both scope and complexity.

South Korea introduced a new mandatory traceability and tracking system for implantable devices, strengthening post-market surveillance obligations for manufacturers selling in that market. UDI requirements are expanding across the region. Post-market reporting, adverse event monitoring, and lifecycle management responsibilities are increasing in China, Japan, Australia, and several ASEAN markets.

Companies that build proactive compliance systems, aligning with ISO 13485 and ISO 14971 from the start, monitoring regulatory changes continuously, and maintaining complete post-market documentation are in a fundamentally stronger position than those reacting to requirements as they emerge.

Regulatory Intelligence: Why Static Knowledge Is Not Enough

APAC regulations are among the fastest-evolving in the world. New guidelines are introduced regularly. Existing frameworks are updated. New reliance pathways are created. Enforcement practices shift.

Without a structured way to monitor these changes, teams rely on fragmented sources like local partners, outdated documentation, or manual tracking which increases submission risk and delays response times when requirements change.

The companies that navigate APAC effectively invest in regulatory intelligence infrastructure before their submissions begin, not after their first deficiency letter arrives.

How RegDesk Supports APAC Submissions

RegDesk’s platform centralizes regulatory intelligence across APAC markets, standardizes documentation while enabling country-specific localization, and tracks submissions and timelines in real time. For teams managing multiple APAC submissions simultaneously, each with different requirements, representatives, and review cultures, a centralized system is the operational foundation that makes coordinated execution possible.

Frequently Asked Questions

What is medical device registration in APAC?

Medical device registration in APAC refers to obtaining regulatory authorization to market a device in countries across the Asia Pacific region. Each country has its own regulatory authority, classification system, and documentation requirements. In practice, this includes preparing technical documentation, meeting clinical evidence expectations, appointing local representatives, and navigating country-level review processes.

How long does APAC medical device registration take?

Timelines vary significantly by country and device classification. Lower-risk devices in some ASEAN markets may be approved within 3–6 months via reliance pathways, while higher-risk devices in China or Japan typically take 12–24 months. Delays most often occur during classification, documentation preparation, and deficiency response, not during the formal review period itself.

What are the biggest challenges in APAC regulatory approvals?

The most common challenges are fragmented regulatory frameworks, language and translation requirements, the need for local representation, limited visibility into regulatory updates, and managing multiple submissions simultaneously without centralized tracking. Failing to evaluate available reliance pathways before submitting is the single most costly avoidable mistake.

Do APAC countries follow the same regulatory framework?

No. While there are ongoing harmonization efforts, particularly through the ASEAN Medical Device Directive and growing bilateral reliance programs, APAC countries largely operate independent regulatory systems with meaningful differences in classification rules, clinical evidence requirements, documentation formats, and approval processes.

How can companies streamline APAC medical device registration?

The most effective approach combines early regulatory intelligence investment, country-specific classification assessment before documentation begins, documentation built with localization in mind from the start, active evaluation of available reliance pathways, and a centralized submission management system that maintains visibility across markets and timelines simultaneously.

What reliance pathways are available in APAC?

Reliance pathways have expanded significantly in 2025–2026. FDA and EU approvals are accepted as the basis for abridged review in Australia, Singapore, Malaysia, India, and many other markets. Singapore and Malaysia launched a bilateral reliance program in September 2025 now moving to permanent implementation. Malaysia and Thailand launched a bilateral pilot in February 2026. The APACMed Regulatory Reliance Pathways Tracker provides the most current market-by-market overview.